Published in Oncotarget on June 28, 2016
Metabolomics enables precision medicine: "A White Paper, Community Perspective". Metabolomics (2016) 0.93
Precision medicine: from pharmacogenomics to pharmacoproteomics. Clin Proteomics (2016) 0.92
Progress in Metabolomics Standardisation and its Significance in Future Clinical Laboratory Medicine. EJIFCC (2016) 0.77
From Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized Medicine. Front Pharmacol (2016) 0.76
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (2012) 8.74
MetaboAnalyst 3.0--making metabolomics more meaningful. Nucleic Acids Res (2015) 4.67
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 3.45
Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A (2009) 3.01
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer (2006) 2.75
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol (2007) 2.50
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst (2013) 2.28
Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc (2010) 2.18
Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics (2012) 2.18
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol (2014) 1.98
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer (2012) 1.91
The kynurenine system and immunoregulation. J Neural Transm (Vienna) (2011) 1.38
Biochemistry of tryptophan in health and disease. Mol Aspects Med (1983) 1.34
Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry (2011) 1.32
Polyamines and cancer: implications for chemotherapy and chemoprevention. Expert Rev Mol Med (2013) 1.18
Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther (2013) 1.11
Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics (2011) 1.07
Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation (2007) 1.06
Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res (2004) 1.02
Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol (2012) 0.99
Cancer: Why tumours eat tryptophan. Nature (2011) 0.99
Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med (2009) 0.99
Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest (2012) 0.98
Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One (2013) 0.97
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol (2013) 0.96
Molecular determinants of trastuzumab efficacy: What is their clinical relevance? Cancer Treat Rev (2013) 0.95
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat (2015) 0.94
The role of polyamine catabolism in anti-tumour drug response. Biochem Soc Trans (2003) 0.92
Pharmacometabonomics and personalized medicine. Ann Clin Biochem (2013) 0.89
Aliphatic polyamines in physiology and diseases. Clin Nutr (2013) 0.89
Pharmacometabolomics of statin response. Clin Pharmacol Ther (2013) 0.86
An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clin Pharmacol Ther (2010) 0.84
Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. J Cell Physiol (2012) 0.84
Polyamine sharing between tubulin dimers favours microtubule nucleation and elongation via facilitated diffusion. PLoS Comput Biol (2009) 0.83
Increased plasma free tryptophan levels in human cancer: a tumor related effect? Anticancer Res (1991) 0.81
Trastuzumab: qui bono? J Natl Cancer Inst (2013) 0.79
Serum polyamines in pre- and post-operative patients with breast cancer corrected by menopausal status. Cancer Lett (2008) 0.79
High-throughput LC-MS/MS based simultaneous determination of polyamines including N-acetylated forms in human saliva and the diagnostic approach to breast cancer patients. Anal Chem (2013) 0.77
Polyamines in human breast cancer and its relations to classical prognostic features: clinical implications. Anticancer Res (1999) 0.76
Extracellular Matrix and Colorectal Cancer: How Surrounding Microenvironment Affects Cancer Cell Behavior? J Cell Physiol (2016) 0.79
Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. Oncotarget (2016) 0.77
An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. Oncotarget (2015) 0.77
Primary extragenital endometrial stromal sarcoma of the lung: first reported case and review of literature. Diagn Pathol (2017) 0.75
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer? Oncotarget (2016) 0.75
New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategy. J Enzyme Inhib Med Chem (2022) 0.75